CA Ⅱ
Carbonic Anhydrase II (CA II) is a cytosolic zinc metalloenzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate and a proton, a reaction central to acid-base homeostasis, carbon dioxide transport, and cellular pH regulation[1][2]. CA II is the best-characterized human carbonic anhydrase isoform and exhibits exceptionally high catalytic efficiency, making it a key regulator of bicarbonate-dependent physiological processes in erythrocytes, kidney, bone, eye, and other tissues[2][3]. Mechanistically, CA II supports bicarbonate transport and acidification pathways that are required for renal bicarbonate reabsorption and osteoclast-mediated bone resorption[1][4]. In disease settings, inherited CA II deficiency causes the autosomal recessive syndrome characterized by osteopetrosis, renal tubular acidosis, and cerebral calcification, providing direct genetic evidence for the essential role of this isoform in bone and renal physiology[4][5]. Compared with related carbonic anhydrase isoforms, CA II is distinguished by its broad tissue distribution, dominant catalytic activity, and well-established involvement in bicarbonate transport metabolons and vascular regulatory processes[3][6]. These characteristics have made CA II one of the most extensively studied experimental models for enzyme catalysis, structure-guided drug discovery, and inhibitor development[3][7]. Sulfonamide-based carbonic anhydrase inhibitors, including clinically used agents, bind the catalytic zinc center and have been widely employed to investigate CA II function and therapeutic modulation in disorders such as glaucoma and other bicarbonate-dependent pathologies[6][7].
References:
- [1]. Sly WS, et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A. 1983 May;80(9):2752-6. [Content Brief]
- [2]. Roy BC, et al. Two-prong inhibitors for human carbonic anhydrase II. J Am Chem Soc. 2004 Oct 20;126(41):13206-7. [Content Brief]
-
CA Ⅱ Related Products (119)
Related Products (119)
-
Recombinant Proteins (3)
-
hCAII-IN-8
0 ImageshCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC50 value of 0.18 μM against hCA II.
-
CAI/II-IN-13
0 ImagesCat. No.: HY-178922CAI/II-IN-13 (Compound 5f) is a CAI/II inhibitor, with IC50 values of 309.16 nM for hCA I and 267.27 nM for hCA II. CAI/II-IN-13 exhibits potent and selective antiproliferative activity against A549 lung cancer cells (IC50 = 0.58 μM). CAI/II-IN-13 can be used for the study of lung cancer.
-
BChE/hCA II-IN-1
0 ImagesCat. No.: HY-178017BChE/hCA II-IN-1 (Compound 20) is a dual-functional inhibitor of Butyrylcholinesterase (BChE) and human carbonic anhydrase II (hCA II) with IC50s of 76.50 and 10.69 μM for BChE and hCA II, respectively. BChE/hCA II-IN-1 can be used for neurodegenerative diseases like Alzheimer's and glaucoma research.
-
CAXII-IN-3
0 ImagesCat. No.: HY-178030CAXII-IN-3 is an effective carbonic anhydrase (CA XII) inhibitor with a Ki of 53 nM. CAXII-IN-3 exhibits selective inhibition against multiple human CA subtypes with Kis of 5.3 μM, 75 nM, 1.9 μM, > 10 μM against CA I, CA II, CA IV and CA IX. CAXII-IN-3 mainly inhibits CA II and XII, and reduces aqueous humor production. CAXII-IN-3 exhibits β3-AR agonistic activity, can dilate retinal blood vessels, and improve optic nerve perfusion. CAXII-IN-3 can be used in the research of ocular disorders such as glaucoma.
-
CAII-IN-12
0 ImagesCat. No.: HY-180056CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research.
-
α-Glucosidase-IN-63
0 ImagesCat. No.: HY-161522CAS No.: 2375866-82-1α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC50=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of Ki= 7.0 nM. α-Glucosidase-IN-63 is orally effective..
-
hCAIX/XII-IN-6
0 ImagesCat. No.: HY-151472CAS No.: 3031666-31-3hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA).
-
BChE-IN-36
0 ImagesCat. No.: HY-169163hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with KA values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC50 values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders.
-
hCAII-IN-9
0 ImageshCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability.
-
β-Glucuronidase/hCAII-IN-2
0 ImagesCat. No.: HY-150977CAS No.: 2816080-13-2β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 670.7 μM and 21.77 μM, respectively.
-
β-Glucuronidase/hCAII-IN-1
0 ImagesCat. No.: HY-150976CAS No.: 2816080-17-6β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 440.1 μM and 4.91 μM, respectively.
-
hCA-IN-1
0 ImagesCat. No.: HY-175245hCA-IN-1 (Compound 5u) is an hCA inhibitor with Ki values of 159.2, 4.8, 15.5, and 2 nM against hCA I, hCA II, hCA IX, and hCA XII, respectively. hCA-IN-1 exhibits broad-spectrum anticancer activity against melanoma, breast, and colon cancer cells. ADME predictions indicate that hCA-IN-1 has good solubility and oral bioavailability. hCA-IN-1 can be used in tumor research.
-
Carbonic anhydrase inhibitor 14
0 ImagesCat. No.: HY-150570CAS No.: 2410402-75-2Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity.
-
Carbonic anhydrase inhibitor 3
0 ImagesCat. No.: HY-142853CAS No.: 2758231-56-8Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits.
-
CAII-IN-15
0 ImagesCat. No.: HY-183283CAII-IN-15 is a potent carbonic anhydrase II (CA II) inhibitor with a hCA II IC50 of 10 nM. CAII-IN-15 elevates cGMP levels, releases nitric oxide, reduces oxidative stress, and exhibits neuroprotective activity in vitro. CAII-IN-15 inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis. CAII-IN-15 reduces Intraocular pressure (IOP) in rabbits. CAII-IN-15 can be used for the research of glaucoma.
-
Carbonic anhydrase-IN-37
0 ImagesCat. No.: HY-180189Carbonic anhydrase-IN-37 (compound 9a) is a potent and orally active carbonic anhydrase (CA) inhibitor with Kis of 9.7 and 1.0 nM for hCA VA and hCA VB, respectively. Carbonic anhydrase-IN-37 shows anti allodynic and antihyperalgesic effects on Paclitaxel (HY-B0015)-induced neuropathic pain in mice. Carbonic anhydrase-IN-37 can be used for neuropathic pain research.
-
CAIX/CAXII-IN-1
0 ImagesCat. No.: HY-146819CAS No.: 2439165-37-2Compound 9 is the most effective against tumor specific Ca ix/ca XII (ki=29.1 and 8.8 nm), so it is possible to evaluate its cytotoxicity and selectivity to HepG-2, HCT-116 and MCF-7 cancer cell lines in vitro, and its IC50 values to tumor cells are 1.78, 1.94 and 3.07, respectively μ M. It showed that it had obvious cytotoxicity.
-
Brinzolamide hydrochloride
0 ImagesCat. No.: HY-B0588ACAS No.: 150937-43-2Synonyms: AL-4862 hydrochlorideBrinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research.
